All
Drug Duo Granted Priority Review for CLL Treatment
October 17th 2018The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Patients with Advanced Lung Cancer Receive Unnecessary Medicine at Hospital Discharge
October 17th 2018The amount of preventative medicines given during hospital admission may be associated with an increased amount prescribed at discharge – resulting in higher costs and an increased risk for drug-drug interactions in patients with advanced lung cancer.
The Naked Truth: Panel Urges Patients to Get Checked from Head to Toe for Melanoma
October 15th 2018The panelists acknowledged that many individuals face barriers to receiving regular skin check-ups. Some people – especially those in rural areas – may not have a dermatologist near them. And even if they do make it in to a doctor’s office for a skin check-up, they may not be checked as thoroughly as they should be.
LOXO-292 Granted Breakthrough Designation for Thyroid Cancer
October 15th 2018The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.
Daily Aspirin Use Could Reduce Ovarian Cancer Risk and Improve Survival
October 14th 2018New research indicates that aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil) or naproxen (Aleve) could not only reduce the risk of ovarian cancer, but also improve survival with daily use.
Committee Supports FDA Approval of CT-P10 for Non-Hodgkin Lymphoma Treatment
October 10th 2018The Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted 16-0 in support of the agency granting approval to CT-P10, a biosimilar of Rituxan (rituximab), which is a drug used to treat non-Hodgkin lymphoma.